North America’s medical devices industry saw a drop of 6.52% in deal activity during June 2021, when compared with the last 12-month average, led by GIC, Hellman & Friedman, The Blackstone Group and The Carlyle Group’s $34bn private equity deal with Medline Industries, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
A total of 86 medical devices industry deals worth $37.2bn were announced for the region in June 2021, against the 12-month average of 92 deals.
Of all the deal types, venture financing saw most activity in June 2021 with 57 transactions, representing a 66.3% share for the region.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
In second place was M&A with 20 deals, followed by private equity deals with nine transactions, respectively capturing a 23.3% and 10.5% share of the overall deal activity for the month.
In terms of value of deals, private equity was the leading category in North America’s medical devices industry with $34.42bn, while venture financing and M&A deals totalled $1.63bn and $1.17bn, respectively.
North America medical devices industry deals in June 2021: Top deals
The top five medical devices deals accounted for 96.1% of the overall value during June 2021.
The combined value of the top five medical devices deals stood at $35.76bn, against the overall value of $37.2bn recorded for the month.
The top five medical devices industry deals of June 2021 tracked by GlobalData were:
1) GIC, Hellman & Friedman, The Blackstone Group and The Carlyle Group’s $34bn private equity deal with Medline Industries
2) The $1bn acquisition deal with Paramit by Tecan Group
3) Counterpoint Global, Janus Henderson Investors, Logos Global Management, Meritech Capital Partners and T Rowe Price Associates’ $276m venture financing of Element Biosciences
4) The $255m venture financing of InSilico Medicine by B Capital Group Management, Baidu Ventures, Bold Capital Partners, CITIC Industrial Investment Fund Management, Deerfield ManagementLP, Eight Roads Ventures, Formic Ventures, Lake Bleu Capital, Lilly Asia ventures, Maison Capital Group, Mirae Asset Capital, Orbimed Advisors, Pavilion Capital Partners, President International Development, Qiming Venture Partners, Sage Partners, Sequoia Capital China, Sinovation Ventures and Warburg Pincus
5) Goldman Sachs Asset Management’s private equity deal with 4G Clinical for $230m.